Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome

Haematologica. 2016 Apr;101(4):e129-32. doi: 10.3324/haematol.2015.138958. Epub 2016 Jan 14.
No abstract available

Keywords: chronic myeloproliferative disorders; cytogenetics and molecular genetics; laboratory hematology.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Calreticulin / genetics*
  • Calreticulin / metabolism
  • DNA Mutational Analysis
  • Gene Expression
  • Humans
  • Janus Kinase 2 / genetics*
  • Janus Kinase 2 / metabolism
  • Mutation
  • Primary Myelofibrosis / diagnosis
  • Primary Myelofibrosis / genetics*
  • Primary Myelofibrosis / mortality
  • Primary Myelofibrosis / pathology
  • Prognosis
  • Receptors, Thrombopoietin / genetics*
  • Receptors, Thrombopoietin / metabolism
  • Survival Analysis
  • Thrombocythemia, Essential / diagnosis
  • Thrombocythemia, Essential / genetics*
  • Thrombocythemia, Essential / mortality
  • Thrombocythemia, Essential / pathology

Substances

  • CALR protein, human
  • Calreticulin
  • Receptors, Thrombopoietin
  • MPL protein, human
  • JAK2 protein, human
  • Janus Kinase 2